Market Research Logo

Global Pulmonary Arterial Hypertension (PAH) Market: Industry Analysis & Outlook (2018-2022)

Global Pulmonary Arterial Hypertension (PAH) Market: Industry Analysis & Outlook (2018-2022)

Pulmonary arterial hypertension (PAH) is one form of pulmonary hypertension (PH) condition, which means high blood pressure in the lungs. Many diseases such as obstructive sleep apnea (OSA), lung diseases, diastolic heart failure and diseases of the left heart can cause the pressures in the pulmonary arteries to elevate but is not pulmonary arterial hypertension. PAH is a life threatening disease characterized by an increase in pulmonary vascular resistance that eventually leads to death. It is a rare disease, affects about 15-70 people per million in the U.S. The symptoms of PAH are difficult to diagnose as the symptoms are common to other diseases.

Pulmonary arterial hypertension is a severe condition and there is no cure to PAH at present time. Many treatments are available to improve symptoms, quality of life and to keep the condition under control. There are currently four classes of drugs approved for the treatment of PAH and 13 approved products are available for PAH in the market across these four drug classes.

The United States is the main contributor to the PAH market with the development of new therapies and increasing cases of pulmonary arterial hypertension. The U.S. has great potential in the years ahead with rising awareness about treatment options of PAH.
The global PAH market is expected to grow in the future due to increasing ageing population, rise in healthcare expenditure, growing women population, increase in obese population and high unmet needs. Key trends of this market include increasing number of cardiovascular diseases, rising government support, and consumption of junk food. However, there are some factors which can hinder the growth of the market which includes patent expiration, high cost and lack of awareness.

The report “Global Pulmonary Arterial Hypertension Market: Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering The United States and Europe region along with the global market. The report profiles the key players in the market including Johnson & Johnson, Gilead Sciences, United Therapeutics and GlaxoSmithKline.


1. Market Overview
1.1 Pulmonary Arterial Hypertension
Table 1: Progression of PAH
1.2 Types of PAH
Table 2: Types of PAH
1.3 Causes and Risk Factors of PAH
1.4 Symptoms
1.5 Diagnosis
1.6 PAH Patient Grouping As Per WHO
Table 3: WHO Functional Classification of Pulmonary Hypertension
1.7 Treatment
1.8 PAH Drugs Classification
1.9 Approved PAH Drugs
Table 4: Approved Drugs to Treat PAH
1.10 PAH Drugs In Development
Table 5: Drugs in Clinical Development for PAH
2. Global Market Analysis
2.1 Global PAH Market by Value
Table 6: Global PAH Market by Value (2013-2017)
2.2 Global PAH Market Forecast by Value
Table 7: Global PAH Market Forecast by Value (2018-2022)
2.3 Global PAH Market by Drug Type
Table 8: Global PAH Market by Drug Type (2017)
2.4 Global ERAs Drugs Market
Table 9: Global ERAs Drugs Market by Value (2013-2017)
2.4.1 Global ERAs Drugs Forecast Market by Value
Table 10: Global ERAs Drugs Forecast Market by Value (2018-2022)
2.4.2 Global Tracleer Revenue
Table 11: Global Tracleer Revenue (2013-2017)
2.4.3 Global Letairis Revenue
Table 12: Global Letairis Revenue (2013-2017)
2.4.4 Global Opsumit Revenue
Table 13: Global Opsumit Revenue (2013-2017)
2.5 Global Prostacyclin Drugs Market
Table 14: Global Prostacyclin Drugs Market by Value (2013-2017)
2.5.1 Global Prostacyclin Drugs Market Forecast by Value
Table 15: Global Prostacyclin Drugs Market Forecast by Value (2018-2022)
2.5.2 Global Tyvaso Revenue
Table 16: Global Tyvaso Revenue (2013-2017)
2.5.3 Global Remodulin Revenue
Table 17: Global Remodulin Revenue (2013-2017)
2.5.4 Global Veletri Revenue
Table 18: Global Veletri Revenue (2013-2017)
2.5.5 Global Orentiram Revenue
Table 19: Global Orentiram Revenue (2013-2017)
2.6 Global PDE Drugs Market
Table 20: Global PDE Drugs Market by Value (2013-2017)
2.6.1 Global PDE Drugs Market Forecast by Value
Table 21: Global PDE Drugs Market Forecast by Value (2018-2022)
2.6.2 Global Revatio Revenue
Table 22: Global Revatio Revenue (2013-2017)
2.6.3 Global Adrcica Revenue
Table 23: Global Adrcica Revenue (2013-2017)
2.7 Global sGC/Adempas Drugs Market
Table 24: Global sGC/Adempas Drugs Market by Value (2014-2017)
2.7.1 Global sGC Drugs Market Forecast by Value
Table 25: Global sGC Drugs Market Forecast (2018-2022)
2.8 Global Ralinepag Drug Revenue
Table 26: Global Ralinepag Drug Revenue Forecast (2022-2025)
3. Regional Market
3.1 The U.S.
3.1.1 The U.S. PAH Population Forecast
Table 27: The U.S. PAH Population Forecast (2021-2025)
3.1.2 The U.S. PAH Incident Population Forecast
Table 28: The U.S. PAH Incident Population Forecast (2021-2025)
3.1.3 The U.S. PAH Population by WHO Patient Class Division
Table 29: The U.S. PAH Population by WHO Patient Class Division (2021)
3.1.4 The U.S. WHO FC Patient Class Forecast
Table 30: The U.S. WHO FC Patient Class Forecast (2021-2025)
3.1.5 The U.S. Ralinepag Revenue
Table 31: The U.S. Ralinepag Revenue (2022-2025)
3.1.6 The U.S. Ralinepag Treated Patients
Table 32: The U.S. Ralinepag Treated Patients (2022-2025)
3.2 Europe
3.2.1 Europe PAH Population Forecast
Table 33: Europe PAH Population Forecast (2021-2025)
3.2.2 Europe PAH Incident Population Forecast
Table 34: Europe PAH Incident Population Forecast (2021-2025)
3.2.3 Europe PAH Population by WHO Patient Class Division
Table 35: Europe PAH Population by WHO Patient Class Division (2021)
3.2.4 Europe WHO FC Patient Class Forecast
Table 36: Europe WHO FC Patient Class Forecast (2021-2025)
3.2.5 Europe Ralinepag Revenue
Table 37: Europe Ralinepag Revenue (2022-2025)
3.2.6 Europe Ralinepag Treated Patients
Table 38: Europe Ralinepag Treated Patients (2022-2025)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increasing Healthcare Spending
Table 39: Global Healthcare Spending Per Capita (2013-2017)
4.1.2 Rising Ageing Population
Table 40: Global Ageing Population (2013-2017)
4.1.3 Accelerating Economic Growth
Table 41: Global GDP Per Capita (2013-2017)
4.1.4 Growing Female Population
Table 42: Global Female Population (2013-2017)
4.1.5 Increase in Obese Population
Table 43: Global Obese Population (2013-2017)
4.1.6 Unmet Medical Needs
4.2 Trend & Developments
4.2.1 Growing Number of Cardiac Diseases
Table 44: Cardiovascular Deaths in the U.S. (2017)
4.2.2 Growing Consumption of Fast Food
4.2.3 Favorable Government Support
4.3 Challenges
4.3.1 High Costs of Diagnosis and Treatment
Table 45: Annual Drugs Cost For PAH Treatment (2017)
4.3.2 Lack of Awareness
4.3.3 Expiry of Patents
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
Table 46: Key Players - Revenue & Market Cap Comparison (2017)
5.1.2 Research and Development Expenditure Comparison
Table 47: Key Players - Research and Development Expenditure Comparison (2017)
6. Company Profiles
6.1 Johnson & Johnson
6.1.1 Business Overview
Table 48: Johnson & Johnson Sales by Segments (2017)
6.1.2 Financial Overview
Table 49: Johnson & Johnson Sales and Net Earnings (2013-2017)
6.1.3 Business Strategies
Table 50: Johnson & Johnson R&D Expenditure (2015-2017)
6.2 United Therapeutics Corporation
6.2.1 Business Overview
Table 51: United Therapeutics Revenue by Product (2017)
6.2.2 Financial Overview
Table 52: United Therapeutics Revenue and Net Income (2013-2017)
6.2.3 Business Strategies
Table 53: United Therapeutics R&D Expenditure (2015-2017)
6.3 GlaxoSmithKline Plc.
6.3.1 Business Overview
Table 54: GlaxoSmithKline Turnover by Segment (2017)
6.3.2 Financial Overview
Table 55: GlaxoSmithKline Turnover and Profit (2013-2017)
6.3.3 Business Strategies
Table 56: GlaxoSmithKline R&D Expenditure (2015-2017)
6.4 Gilead Sciences
6.4.1 Business Overview
Table 57: Gilead Sciences Revenue by Geographical Region (2017)
6.4.2 Financial Overview
Table 58: Gilead Sciences Revenue and Net Income (2013-2017)
6.4.3 Business Strategies
Table 59: Gilead Sciences R&D Expenditure (2015-2017)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report